Page last updated: 2024-12-07

tetranitrotetrazolium blue

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID121822
CHEMBL ID3856120
SCHEMBL ID2863232
MeSH IDM0090841

Synonyms (37)

Synonym
tetranitrotetrazolium blue
tetranitro blue tetrazolium chloride
nsc-121208
tnbt
1184-43-6
blue p-nitrotetrazolium chloride
tetranitro blue tetrazolium
2h-tetrazolium, 2,2'-(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[3,5-bis(4-nitrophenyl)-, dichloride
tetranitroblue tetrazolium chloride
tetranitroblue tetrazolium chloride, >=85% (at)
2h-tetrazolium, 2,2'-(3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)bis(3,5-bis(4-nitrophenyl)-, dichloride
2h-tetrazolium, 2,2'-(3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)bis(3,5-bis(4-nitrophenyl)-, chloride (1:2)
3,3'-(3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)bis(2,5-bis(p-nitrophenyl)-2h-tetrazolium) dichloride
nsc 121208
tetranitro blue tetrazolium chloride hydrate
einecs 214-665-1
SCHEMBL2863232
J-610058
mfcd00036338
CHEMBL3856120
2-[4-[4-[3,5-bis(4-nitrophenyl)tetrazol-2-ium-2-yl]-3-methoxyphenyl]-2-methoxyphenyl]-3,5-bis(4-nitrophenyl)tetrazol-2-ium;chloride
tetranitro blue tetrazolium [for biochemical research]
3,3'-(3,3'-dimethoxybiphenyl-4,4'-diyl)bis(2,5-bis(4-nitrophenyl)-2h-tetrazol-3-ium) chloride
AMY27010
2-[4-[4-[3,5-bis(4-nitrophenyl)tetrazol-2-ium-2-yl]-3-methoxyphenyl]-2-methoxyphenyl]-3,5-bis(4-nitrophenyl)tetrazol-2-ium;dichloride
T71618
CS-0142430
DTXSID001340653
HY-D1193
nitroblue monotetrazolium chloride
2,2',5,5'-tetrakis-p-(nitrophenyl)-3,3'-bis(3,3'-dimethoxy-4,4'-diphenylene)ditetrazolium chloride
2h-tetrazolium, 3,3'-(3,3'-dimethoxy-4,4'-biphenylylene)bis[2,5-bis(p-nitrophenyl)-, dichloride
2,2',5,5'-tetrakis(p-nitrophenyl)-3,3'-(3,3'-dimethoxy-4,4'-diphenylene)ditetrazolium chloride
MPL95XJE37
2h-tetrazolium, 2,2'-(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[3,5-bis(4-nitrophenyl)-, chloride (1:2)
[3,3'-(3,3'-dimethoxy-4,4'-biphenylylene)bis[2,5-bis(p-nitrophenyl)-2h-tetrazolium chloride]]
2,2',5,5'-tetra-p-nitrophenyl-3,3'-(3,3'-dimethoxy-4,4'-biphenylene)ditetrazolium chloride
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID317435Toxicity in CHO cells2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Anti-Plasmodium activity of tetrazolium salts.
AID735073Displacement of SYBR green I from salmon testes DNA assessed as compound treated with DNA followed by SYBR green I added relative to control2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
The interaction of imidazole-, imidazolium-, and tetrazolium-containing compounds with DNA.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-199025 (83.33)18.7374
1990's3 (10.00)18.2507
2000's1 (3.33)29.6817
2010's1 (3.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.74 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index4.20 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.23%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (96.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]